James T McCracken1, James J McGough2, Sandra K Loo2, Jennifer Levitt2, Melissa Del'Homme2, Jennifer Cowen3, Alexandra Sturm2, Fiona Whelan2, Gerhard Hellemann2, Catherine Sugar4, Robert M Bilder5. 1. David Geffen School of Medicine at University of California, Los Angeles (UCLA), and the Jane and Terry Semel Institute for Neuroscience and Human Behavior at UCLA. Electronic address: jmccracken@mednet.ucla.edu. 2. David Geffen School of Medicine at University of California, Los Angeles (UCLA), and the Jane and Terry Semel Institute for Neuroscience and Human Behavior at UCLA. 3. UCLA and the Semel Institute for Neuroscience and Human Behavior at UCLA. 4. David Geffen School of Medicine at University of California, Los Angeles (UCLA), and the Jane and Terry Semel Institute for Neuroscience and Human Behavior at UCLA; UCLA School of Public Health. 5. David Geffen School of Medicine at University of California, Los Angeles (UCLA), and the Jane and Terry Semel Institute for Neuroscience and Human Behavior at UCLA; UCLA College of Letters and Science.
Abstract
OBJECTIVE: Because models of attention-deficit/hyperactivity disorder (ADHD) therapeutics emphasize benefits of both enhanced dopaminergic and noradrenergic signaling, strategies to enhance D1 and α2A agonism may yield enhanced clinical and cognitive responses. This study tested the hypothesis that combined effects of a dopamine and noradrenergic agonist, d-methylphenidate extended-release (DMPH) with guanfacine (GUAN), an α2A receptor agonist, would be clinically superior to either monotherapy and would have equal tolerability. METHOD: An 8-week, double-blind, 3-arm, comparative trial randomized 7- to 14-year-olds with DSM-IV ADHD to GUAN (1-3 mg/day), DMPH (5-20 mg/day), or a combination (COMB) with fixed-flexible dosing. Outcome measures were the ADHD Rating Scale IV (ADHD-RS-IV) and the Clinical Global Impression-Improvement (CGI-I) scale. Data on adverse events and safety measures were obtained. RESULTS: A total of 207 participants were randomized and received drug. Analyses showed significant treatment group main effects for ADHD-RS-IV ADHD total (p = .0001) and inattentive symptoms (p = .0001). COMB demonstrated small but consistently greater reductions in ADHD-RS-IV Inattentive subscale scores versus monotherapies (DMPH: p = .05; f(2) = .02; and GUAN: p = .02; f(2) = .02), and was associated with a greater positive response rate by CGI-I (p = .01). No serious cardiovascular events occurred. Sedation, somnolence, lethargy, and fatigue were greater in both guanfacine groups. All treatments were well tolerated. CONCLUSION: COMB showed consistent evidence of clinical benefits over monotherapies, possibly reflecting advantages of greater combined dopaminergic and α2A agonism. Adverse events were generally mild to moderate, and COMB treatment showed no differences in safety or tolerability. CLINICAL TRIAL REGISTRATION INFORMATION: Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder (Project1); http://clinicaltrials.gov/; NCT00429273.
RCT Entities:
OBJECTIVE: Because models of attention-deficit/hyperactivity disorder (ADHD) therapeutics emphasize benefits of both enhanced dopaminergic and noradrenergic signaling, strategies to enhance D1 and α2A agonism may yield enhanced clinical and cognitive responses. This study tested the hypothesis that combined effects of a dopamine and noradrenergic agonist, d-methylphenidate extended-release (DMPH) with guanfacine (GUAN), an α2A receptor agonist, would be clinically superior to either monotherapy and would have equal tolerability. METHOD: An 8-week, double-blind, 3-arm, comparative trial randomized 7- to 14-year-olds with DSM-IV ADHD to GUAN (1-3 mg/day), DMPH (5-20 mg/day), or a combination (COMB) with fixed-flexible dosing. Outcome measures were the ADHD Rating Scale IV (ADHD-RS-IV) and the Clinical Global Impression-Improvement (CGI-I) scale. Data on adverse events and safety measures were obtained. RESULTS: A total of 207 participants were randomized and received drug. Analyses showed significant treatment group main effects for ADHD-RS-IV ADHD total (p = .0001) and inattentive symptoms (p = .0001). COMB demonstrated small but consistently greater reductions in ADHD-RS-IV Inattentive subscale scores versus monotherapies (DMPH: p = .05; f(2) = .02; and GUAN: p = .02; f(2) = .02), and was associated with a greater positive response rate by CGI-I (p = .01). No serious cardiovascular events occurred. Sedation, somnolence, lethargy, and fatigue were greater in both guanfacine groups. All treatments were well tolerated. CONCLUSION:COMB showed consistent evidence of clinical benefits over monotherapies, possibly reflecting advantages of greater combined dopaminergic and α2A agonism. Adverse events were generally mild to moderate, and COMB treatment showed no differences in safety or tolerability. CLINICAL TRIAL REGISTRATION INFORMATION: Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder (Project1); http://clinicaltrials.gov/; NCT00429273.
Authors: Susheel Vijayraghavan; Min Wang; Shari G Birnbaum; Graham V Williams; Amy F T Arnsten Journal: Nat Neurosci Date: 2007-02-04 Impact factor: 24.884
Authors: J M Swanson; H C Kraemer; S P Hinshaw; L E Arnold; C K Conners; H B Abikoff; W Clevenger; M Davies; G R Elliott; L L Greenhill; L Hechtman; B Hoza; P S Jensen; J S March; J H Newcorn; E B Owens; W E Pelham; E Schiller; J B Severe; S Simpson; B Vitiello; K Wells; T Wigal; M Wu Journal: J Am Acad Child Adolesc Psychiatry Date: 2001-02 Impact factor: 8.829
Authors: Joseph Biederman; Raun D Melmed; Anil Patel; Keith McBurnett; Jennifer Konow; Andrew Lyne; Noreen Scherer Journal: Pediatrics Date: 2008-01 Impact factor: 7.124
Authors: W Burleson Daviss; Nick C Patel; Adelaide S Robb; Michael P McDERMOTT; Oscar G Bukstein; William E Pelham; Donna Palumbo; Peter Harris; Floyd R Sallee Journal: J Am Acad Child Adolesc Psychiatry Date: 2008-02 Impact factor: 8.829
Authors: Agatha Lenartowicz; Holly Truong; Giulia C Salgari; Robert M Bilder; James McGough; James T McCracken; Sandra K Loo Journal: J Child Psychol Psychiatry Date: 2019-03-18 Impact factor: 8.982
Authors: Gregory R Sayer; James J McGough; Jennifer Levitt; Jennifer Cowen; Alexandra Sturm; Edward Castelo; James T McCracken Journal: J Child Adolesc Psychopharmacol Date: 2016-08-02 Impact factor: 2.576
Authors: Sarah C O S Padilha; Suzane Virtuoso; Fernanda S Tonin; Helena H L Borba; Roberto Pontarolo Journal: Eur Child Adolesc Psychiatry Date: 2018-02-19 Impact factor: 4.785
Authors: Alexandra Sturm; Michelle Rozenman; John C Piacentini; James J McGough; Sandra K Loo; James T McCracken Journal: Child Psychiatry Hum Dev Date: 2018-10
Authors: Alexandra Sturm; Emily J Ricketts; Joseph F McGuire; Juliette Lerner; SoJeong Lee; Sandra K Loo; James J McGough; Susanna Chang; Douglas W Woods; James McCracken; John Piacentini Journal: Psychiatry Res Date: 2021-08-05 Impact factor: 11.225